Tags

Type your tag names separated by a space and hit enter

The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection.
Vaccine. 2017 01 03; 35(1):10-18.V

Abstract

The persistent public health threat of infection with the Middle East respiratory syndrome coronavirus (MERS-CoV) highlights the need for an effective MERS-CoV vaccine. Previous studies have focused mainly on the receptor-binding domain (RBD) on the spike protein of MERS-CoV. Herein, we investigated the immunogenicity and protective potential of the recombinant N-terminal domain (rNTD) of spike proteins as a vaccine candidate. BALB/c mice vaccinated with 5 or 10μg of rNTD protein demonstrated a significant humoral immune response (serum IgG and neutralizing activity). Additionally, according to the enzyme-linked immunospot, intracellular cytokine staining, and cytometric bead array assays, significant and functional T-cell immunity was induced by 10μg of the rNTD vaccination with aluminum and CpG adjuvant. Furthermore, rNTD-immunized mice showed reduced lung abnormalities in a MERS-CoV-challenge mouse model transfected with an adenoviral vector expressing human DPP4, showing protection consistent with that found with rRBD vaccination. These data show that rNTD induced potent cellular immunity and antigen-specific neutralizing antibodies in mice and that it demonstrated protective capacity against a viral challenge, indicating that rNTD is a vaccine candidate against MERS-CoV infection.

Links

Publisher Full Text
ncbi.nlm.nih.gov
linkinghub.elsevier.com
PMC Free PDF
Aggregator Full Text

Authors+Show Affiliations

Jiaming L
Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China; Department of Pathogenic Biology, Hebei Medical University, Shijiazhuang 050017, China.
Yanfeng Y
Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences (CAMS) & Comparative Medicine Center, Peking Union Medical Collage (PUMC), Key Laboratory of Human Disease Comparative Medicine, Ministry of Health, Beijing, China.
Yao D
Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China.
Yawei H
CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.
Linlin B
Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences (CAMS) & Comparative Medicine Center, Peking Union Medical Collage (PUMC), Key Laboratory of Human Disease Comparative Medicine, Ministry of Health, Beijing, China.
Baoying H
Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China.
Jinghua Y
CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.
Gao GF
Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.
Chuan Q
Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences (CAMS) & Comparative Medicine Center, Peking Union Medical Collage (PUMC), Key Laboratory of Human Disease Comparative Medicine, Ministry of Health, Beijing, China.
Wenjie T
Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China. Electronic address: tanwj28@163.com.

MeSH

AnimalsAntibodies, NeutralizingAntibodies, ViralCoronavirus InfectionsDisease Models, AnimalFemaleImmunoassayImmunoglobulin GLungMice, Inbred BALB CMiddle East Respiratory Syndrome CoronavirusSpike Glycoprotein, CoronavirusT-LymphocytesVaccines, SyntheticViral Vaccines

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

27899228

Citation

Jiaming, Lan, et al. "The Recombinant N-terminal Domain of Spike Proteins Is a Potential Vaccine Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection." Vaccine, vol. 35, no. 1, 2017, pp. 10-18.
Jiaming L, Yanfeng Y, Yao D, et al. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Vaccine. 2017;35(1):10-18.
Jiaming, L., Yanfeng, Y., Yao, D., Yawei, H., Linlin, B., Baoying, H., Jinghua, Y., Gao, G. F., Chuan, Q., & Wenjie, T. (2017). The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Vaccine, 35(1), 10-18. https://doi.org/10.1016/j.vaccine.2016.11.064
Jiaming L, et al. The Recombinant N-terminal Domain of Spike Proteins Is a Potential Vaccine Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection. Vaccine. 2017 01 3;35(1):10-18. PubMed PMID: 27899228.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. AU - Jiaming,Lan, AU - Yanfeng,Yao, AU - Yao,Deng, AU - Yawei,Hu, AU - Linlin,Bao, AU - Baoying,Huang, AU - Jinghua,Yan, AU - Gao,George F, AU - Chuan,Qin, AU - Wenjie,Tan, Y1 - 2016/11/26/ PY - 2016/05/13/received PY - 2016/11/08/revised PY - 2016/11/18/accepted PY - 2016/12/3/pubmed PY - 2017/12/16/medline PY - 2016/12/1/entrez KW - Animal model KW - MERS-CoV KW - Mice KW - NTD KW - RBD KW - Vaccine SP - 10 EP - 18 JF - Vaccine JO - Vaccine VL - 35 IS - 1 N2 - The persistent public health threat of infection with the Middle East respiratory syndrome coronavirus (MERS-CoV) highlights the need for an effective MERS-CoV vaccine. Previous studies have focused mainly on the receptor-binding domain (RBD) on the spike protein of MERS-CoV. Herein, we investigated the immunogenicity and protective potential of the recombinant N-terminal domain (rNTD) of spike proteins as a vaccine candidate. BALB/c mice vaccinated with 5 or 10μg of rNTD protein demonstrated a significant humoral immune response (serum IgG and neutralizing activity). Additionally, according to the enzyme-linked immunospot, intracellular cytokine staining, and cytometric bead array assays, significant and functional T-cell immunity was induced by 10μg of the rNTD vaccination with aluminum and CpG adjuvant. Furthermore, rNTD-immunized mice showed reduced lung abnormalities in a MERS-CoV-challenge mouse model transfected with an adenoviral vector expressing human DPP4, showing protection consistent with that found with rRBD vaccination. These data show that rNTD induced potent cellular immunity and antigen-specific neutralizing antibodies in mice and that it demonstrated protective capacity against a viral challenge, indicating that rNTD is a vaccine candidate against MERS-CoV infection. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/27899228/The_recombinant_N_terminal_domain_of_spike_proteins_is_a_potential_vaccine_against_Middle_East_respiratory_syndrome_coronavirus__MERS_CoV__infection_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(16)31135-5 DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓45 ↑56]

Related Citations

More